

Methods and compositions for the activation of gamma-delta t-cells

Classifications

- [C12N15/86](#) Viral vectors
- [A61K31/675](#) Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- [A61K31/7105](#) Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- [A61K38/16](#) Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- [A61P35/00](#) Antineoplastic agents
- [A61P43/00](#) Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- [C12N15/113](#) Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- [C12N15/1137](#) Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
- [C12N5/00](#) Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- [C12N5/0636](#) T lymphocytes
- [A61K2039/5158](#) Antigen-pulsed cells, e.g. T-cells
- [A61K48/00](#) Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- [C12N2310/14](#) Type of nucleic acid interfering N.A.
- [C12N2310/141](#) MicroRNAs, miRNAs
- [C12N2310/531](#) Stem-loop; Hairpin
- [C12N2740/15043](#) Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

IL260594B

Israel



Find Prior Art



Similar

Other languages: [Hebrew](#)

Worldwide applications

2017 • [EP](#) [CA](#) [EP](#) [IL](#) [WO](#) [JP](#) [CN](#) [IL](#) [CN](#) [CN](#) [DK](#) [AU](#) [US](#) [US](#) [US](#) [US](#)
 2018 • [US](#) [IL](#) [US](#) 2019 • [US](#) 2021 • [JP](#) [AU](#) 2022 • [US](#) 2023 • [JP](#)

Application IL260594A events

2018-07-15 • Application filed by American Gene Tech Int Inc

2021-01-31 • Publication of IL260594B

Info: [Patent citations \(152\)](#), [Cited by \(14\)](#), [Legal events](#), [Similar documents](#), [Priority and Related Applications](#)

External links: [Espacenet](#), [Global Dossier](#), [Discuss](#)

■ [C12N2750/14143](#) Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

[Hide more classifications](#)

Landscapes

Health & Medical Sciences



Life Sciences & Earth Sciences



Show more

Patent Citations (152)

Publication number	Priority date	Publication date	Assignee	Title
Family To Family Citations				
US5668255A	1984-06-07	1997-09-16	Seragen, Inc.	Hybrid molecules having translocation region and cell-binding region
WO1993024632A1	1992-05-22	1993-12-09	Dana Farber Cancer Institute	Hybrid siv/hiv-1 viral vectors and monkey model for aids
AU6014094A	1992-12-02	1994-06-22	Baylor College Of Medicine	Episomal vectors for gene therapy
WO1995002697A1	1993-07-13	1995-01-26	Rhone-Poulenc Rorer S.A.	Defective adenovirus vectors and use thereof in gene therapy
CA2265460A1	1996-09-11	1998-03-19	The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services	Aav4 vector and uses thereof
WO1999009139A1	1997-08-15	1999-02-25	Rubicon Laboratory, Inc.	Retrovirus and viral vectors
WO1999021979A1	1997-10-28	1999-05-06	Maxygen, Inc.	Human papillomavirus vectors
JP2002506652A	1998-03-20	2002-03-05	トラスティーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア	Compositions and methods for helper-free production of recombinant adeno-associated virus
DK1115290T3	1998-10-01	2009-06-22	Univ Southern California	Retroviral gene delivery system and methods for its use
US6156514A	1998-12-03	2000-12-05	Sunol Molecular Corporation	Methods for making recombinant cells

US6410013B1	1999-01-25	2002-06-25	Musc Foundation For Research Development	Viral vectors for use in monitoring HIV drug resistance
WO2000072886A1	1999-05-26	2000-12-07	Dana-Farber Cancer Institute, Inc.	Episomally replicating lentiviral vectors
AU2001257611A1	2000-04-28	2001-11-12	Avigen, Inc.	Polynucleotides for use in recombinant adeno-associated virus virion production
AU2001261515A1	2000-05-12	2001-11-26	The Regents Of The University Of California	Treatment of human papillomavirus (hpv)-infected cells
WO2001091802A1 *	2000-05-30	2001-12-06	Baylor College Of Medicine	Chimeric viral vectors for gene therapy
NO314588B1	2000-09-04	2003-04-14	Bionor Immuno As	HIV peptides, antigens, vaccine composition, immunoassay test kits and a method for detecting antibodies induced by HIV
US7122181B2 *	2000-12-19	2006-10-17	Research Development Foundation	Lentiviral vector-mediated gene transfer and uses thereof
US20030119770A1	2001-08-02	2003-06-26	Zhennan Lai	Intercellular delivery of a herpes simplex virus VP22 fusion protein from cells infected with lentiviral vectors
WO2003015708A2	2001-08-18	2003-02-27	Myriad Genetics, Inc	Composition and method for treating hiv infection
US7737124B2	2001-09-13	2010-06-15	California Institute Of Technology	Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell
WO2003040311A2	2001-10-25	2003-05-15	The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services	Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4
US20070203333A1	2001-11-30	2007-08-30	Mcswiggen James	RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
CA2479530A1	2002-03-20	2003-10-02	Massachusetts Institute Of Technology	Hiv therapeutic
US20040142416A1	2002-04-30	2004-07-22	Laipis Philip J.	Treatment for phenylketonuria
WO2004037847A2	2002-05-07	2004-05-06	Chiron Corporation	Hiv envelope-cd4 complexes and hybrids
US7199107B2	2002-05-23	2007-04-03	Isis Pharmaceuticals, Inc.	Antisense modulation of kinesin-like 1 expression
US20040161412A1	2002-08-22	2004-08-19	The Cleveland Clinic Foundation	Cell-based VEGF delivery
DK1545204T3	2002-09-06	2016-11-14	The Government Of The Us Secretary Dept Of Health And Human Services	Immunotherapy with in vitro selected antigen-specific lymphocytes following non-myeloablative lymphodepletive chemotherapy
JP2006505288A	2002-11-04	2006-02-16	ユニバーシティー オブ マサチューセッツ	Allele-specific RNA interference

AU2003283174A1	2002-12-11	2004-06-30	Cytos Biotechnology Ag	Method for protein production
WO2004104591A2 *	2003-05-23	2004-12-02	Institut National De La Sante Et De La Recherche Medicale	Improvements to gamma delta t cell-mediated therapy
EP1644508A1	2003-07-11	2006-04-12	Cytos Biotechnology AG	Gene expression system
US20050019927A1	2003-07-13	2005-01-27	Markus Hildinger	DECREASING GENE EXPRESSION IN A MAMMALIAN SUBJECT IN VIVO VIA AAV-MEDIATED RNAi EXPRESSION CASSETTE TRANSFER
US20050138677A1	2003-09-16	2005-06-23	Pfister Herbert J.	Transgenic animal model for the treatment of skin tumors
WO2005028634A2	2003-09-18	2005-03-31	Emory University	Improved mva vaccines
WO2005033282A2	2003-10-01	2005-04-14	Pharmacia & Upjohn Company Llc	Polyamide compositions and therapeutic methods for treatment of human papilloma virus
US20080039413A1	2003-10-21	2008-02-14	Morris David W	Novel compositions and methods in cancer
EP1753777B1	2004-02-25	2014-05-07	Dana-Farber Cancer Institute, Inc.	METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF HIV INFECTION USING TRIM5a
EP1737956A2	2004-03-01	2007-01-03	Massachusetts Institute of Technology	Rnai-based therapeutics for allergic rhinitis and asthma
TWI439284B	2004-04-09	2014-06-01	Abbvie Biotechnology Ltd	Multiple-variable dose regimen for treating tnfa-related disorders
US20080227736A1	2004-06-03	2008-09-18	Regents Of The University Of California,	Targeting Pseudotyped Retroviral Vectors
WO2006012221A2	2004-06-25	2006-02-02	The Regents Of The University Of California	Target cell-specific short interfering rna and methods of use thereof
WO2006023491A2	2004-08-16	2006-03-02	The Cbr Institute For Biomedical Research, Inc.	Method of delivering rna interference and uses thereof
WO2006039721A2 *	2004-10-08	2006-04-13	The Board Of Trustees Of The University Of Illinois	Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
EP1647595A1	2004-10-15	2006-04-19	Academisch Medisch Centrum bij de Universiteit van Amsterdam	Nucleic acids against viruses, in particular HIV
WO2006048215A1	2004-11-02	2006-05-11	Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa	Adenoviral amplicon and producer cells for the production of replication-defective adenoviral vectors, methods of preparation and use thereof
US7790446B2	2005-02-11	2010-09-07	Kosagen Cell Factory Oü	Vectors, cell lines and their use in obtaining extended episomal maintenance replication of hybrid plasmids and expression of gene products

EP2573185A3 *	2005-02-16	2013-06-05	Lentigen Corporation	Lentiviral vectors and their use
DK2002003T3	2005-05-27	2016-03-21	Ospedale San Raffaele Srl	Gene vector comprising miRNA
US20070032443A1 *	2005-08-02	2007-02-08	Jaeseob Kim	Therapy for Alzheimer's disease
WO2007015122A1 *	2005-08-02	2007-02-08	Genexel, Inc.	Therapy for alzheimer's disease
WO2007056388A2	2005-11-07	2007-05-18	The General Hospital Corporation	Compositions and methods for modulating poly (adp-ribose) polymerase activity
WO2007133674A2	2006-05-12	2007-11-22	Lentigen Corporation	Lentiviral vector compositions, methods and applications
US8535897B2 *	2006-06-19	2013-09-17	The Trustees Of Columbia University In The City Of New York	Assays for non-apoptotic cell death and uses thereof
US20080003225A1	2006-06-29	2008-01-03	Henri Vie	Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors
WO2008008719A2	2006-07-10	2008-01-17	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the myc gene
EP1878440A1	2006-07-13	2008-01-16	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds
CN101516365A *	2006-07-26	2009-08-26	诺瓦提斯公司	Inhibitors of undecaprenyl pyrophosphate synthase
US20080199961A1 *	2006-08-25	2008-08-21	Avi Biopharma, Inc.	ANTISENSE COMPOSITION AND METHOD FOR INHIBITION OF miRNA BIOGENESIS
WO2008100292A2 *	2006-10-16	2008-08-21	Genelux Corporation	Modified vaccinia virus strains for use in diagnostic and therapeutic methods
ES2639568T3	2007-01-23	2017-10-27	Janssen Pharmaceutica Nv	Method to design a drug regimen for HIV-infected patients
CA2682694A1 *	2007-04-12	2008-10-23	The Board Of Trustees Of The University Of Illinois	Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps
US20080293142A1	2007-04-19	2008-11-27	The Board Of Regents For Oklahoma State University	Multiple shRNA Expression Vectors and Methods of Construction
EP2008656A1	2007-06-28	2008-12-31	Bergen Teknologioverforing AS	Compositions for the treatment of hyperphenylalaninemia
US8673477B2	2008-06-16	2014-03-18	Polyplus Battery Company	High energy density aqueous lithium/air-battery cells
WO2009026328A2	2007-08-21	2009-02-26	Immune Disease Institute, Inc.	Methods of delivery of agents to leukocytes and endothelial cells

CA3018281C	2007-09-28	2022-02-22	Anthrogenesis Corporation	Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
EP2090659A1	2008-02-14	2009-08-19	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Infectious particle, process for its preparation and use thereof
GB0810209D0	2008-06-04	2008-07-09	Cambridge Entpr Ltd	Pluripotency associated epigenetic factor
US8629334B2	2008-07-16	2014-01-14	University Of Florida Research Foundation, Inc.	Viral-based transient-expression vector system for trees
WO2010022195A2	2008-08-20	2010-02-25	Virxsys Corporation	Non-integrating lenti/adeno-associated virus hybrid vector system
EP2342321B1	2008-09-17	2018-04-11	Isogenis, Inc.	Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof
WO2010045659A1	2008-10-17	2010-04-22	American Gene Technologies International Inc.	Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
US8734795B2	2008-10-31	2014-05-27	Biogen Idec Ma Inc.	Light targeting molecules and uses thereof
WO2010051521A1	2008-10-31	2010-05-06	Lentigen Corporation	Cell therapy product for the treatment of hiv infection
WO2011071476A2	2008-11-14	2011-06-16	Life Technologies Corporation	Compositions and methods for engineering cells
EP2191834A1	2008-11-26	2010-06-02	Centre National De La Recherche Scientifique (Cnrs)	Compositions and methods for treating retrovirus infections
US20120114618A1	2009-03-26	2012-05-10	The Regents Of The University Of California	Mesenchymal Stem Cells Producing Inhibitory RNA for Disease Modification
WO2010117974A2	2009-04-09	2010-10-14	Stemcyte Inc.	Hiv-resistant stem cells and uses thereof
EP2419113B1	2009-04-13	2017-05-10	Apceth GmbH & Co. KG	Engineered mesenchymal stem cells and method of using same to treat tumors
EP2425001A4	2009-04-30	2012-11-14	Univ California	Combination anti-hiv vectors, targeting vectors, and methods of use
EP3329772B1	2009-07-15	2019-10-16	Calimmune, Inc.	Dual vector for inhibition of human immunodeficiency virus
US20120027725A1 *	2009-11-30	2012-02-02	Galvin Jeffrey A	Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules to treat liver cancer
CN101805750B *	2009-12-29	2011-11-30	浙江大学	Construction and application of farnesyl pyrophosphoric acid synthetase RNA (Ribonucleic Acid) interference recombinant lentivirus vector
CN102782136A	2010-02-18	2012-11-14	爱默蕾大学	Vectors expressing HIV antigens and GM-CSF and related methods for generating an immune response

WO2011119942A1	2010-03-25	2011-09-29	Vistagen Therapeutics, Inc.	Induction of ips cells using transient episomal vectors
WO2011133687A2 *	2010-04-20	2011-10-27	President And Fellows Of Harvard College	Methods and compositions for inhibition of beta2-adrenergic receptor degradation
LT2561078T	2010-04-23	2019-01-10	Cold Spring Harbor Laboratory	NOVEL STRUCTURALLY DESIGNED shRNAs
US20110293571A1 *	2010-05-28	2011-12-01	Oxford Biomedica (Uk) Ltd.	Method for vector delivery
WO2012020757A1	2010-08-10	2012-02-16	タカラバイオ株式会社	Production method for cell populations
US20130281493A1	2010-10-07	2013-10-24	The Trustees Of The University Of Columbia In The City Of New York	Method for Treating Cancer Harboring a p53 Mutation
WO2012061075A2	2010-10-25	2012-05-10	The Regents Of The University Of California	Hiv resistant and functional hematopoietic stem/progenitor cells and macrophages from induced pluripotent stem cells
CN108744262A	2010-11-23	2018-11-06	普莱萨格生命科学公司	Treatment and composition for for physical delivery
WO20121115980A1	2011-02-22	2012-08-30	California Institute Of Technology	Delivery of proteins using adeno-associated virus (aav) vectors
US9226976B2 *	2011-04-21	2016-01-05	University Of Massachusetts	RAAV-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
US9358250B2	2011-10-15	2016-06-07	Genentech, Inc.	Methods of using SCD1 antagonists
EP2782596A4	2011-11-22	2015-07-29	Philadelphia Children Hospital	Virus vectors for highly efficient transgene delivery
US9745631B2 *	2011-12-20	2017-08-29	Dana-Farber Cancer Institute, Inc.	Methods for diagnosing and treating oncogenic kras-associated cancer
BR112014019431A8	2012-02-07	2017-07-11	Global Bio Therapeutics Usa Inc	COMPARTMENTALIZED METHOD OF DELIVERY OF NUCLEIC ACID AND COMPOSITIONS AND USES THEREOF
WO2013174404A1	2012-05-23	2013-11-28	Ganymed Pharmaceuticals Ag	Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
AU2013273483A1	2012-06-06	2014-12-11	Bionor Immuno As	Vaccine
WO2014016817A2	2012-07-17	2014-01-30	Universite De Geneve	Nucleic acids for down-regulation of gene expression
CA2922005A1	2012-09-27	2014-04-03	Population Diagnostics, Inc.	Methods and compositions for screening and treating developmental disorders
JP6391582B2	2012-11-13	2018-09-19	コディアック バイオサイエンシズ インコーポレイテッド	Methods for delivering therapeutic agents
CA2892448A1	2012-12-05	2014-06-12	Sangamo Biosciences, Inc.	Methods and compositions for regulation of

				metabolic disorders
US9642921B2	2012-12-20	2017-05-09	Tocagen Inc.	Cancer combination therapy and recombinant vectors
WO2014117050A2 *	2013-01-26	2014-07-31	Mirimus, Inc.	Modified mirna as a scaffold for shrna
CN103184224A	2013-04-03	2013-07-03	衡阳师范学院	Triple minRNA for resisting virus infection of aids and construction method thereof
WO2014187881A1	2013-05-21	2014-11-27	Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V.	Isoforms of gata6 and nkx2-1 as markers for diagnosis and therapy of cancer and as targets for anti-cancer therapy
KR20160011645A	2013-06-03	2016-02-01	떼라백띠스	LENTIVIRAL VECTORS CONTAINING AN MHC CLASS I, MHC CLASS II OR β 2 MICROGLOBULIN UPSTREAM PROMOTER SEQUENCE
AU2014296059B2	2013-08-02	2020-12-10	The Regents Of The University Of California	Engineering antiviral T cell immunity through stem cells and chimeric antigen receptors
WO2015042308A2	2013-09-18	2015-03-26	City Of Hope	Rna-based hiv inhibitors
AU2014340083B2	2013-10-22	2019-08-15	Translate Bio, Inc.	mRNA therapy for phenylketonuria
CN106459995B	2013-11-07	2020-02-21	爱迪塔斯医药有限公司	CRISPR-associated methods and compositions using dominant grnas
EP2878674A1	2013-11-28	2015-06-03	Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC)	Stable episomes based on non-integrative lentiviral vectors
WO2015148926A1	2014-03-28	2015-10-01	Regents Of The University Of Minnesota	Polypeptides, cells, and methods involving engineered cd16
CA2946312A1	2014-04-23	2015-10-29	Juno Therapeutics, Inc.	Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
PL3689899T3 *	2014-04-25	2022-01-31	2Seventy Bio, Inc.	Mnd promoter chimeric antigen receptors
DK3851537T3	2014-04-25	2024-03-18	Genethon	TREATMENT OF HYPERBILIRUBINAMIA
CA2955254A1	2014-08-29	2016-03-03	Immunomedics, Inc.	Identification of cancer genes by in-vivo fusion of human cancer cells and animal cells
SI3197472T1	2014-09-22	2022-01-31	Tanea Medical Ab	Recombinant phe-free proteins for use in the treatment of phenylketonuria
AU2015329696A1	2014-10-10	2017-04-27	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Methods to eliminate cancer stem cells by targeting CD47
CN107405357B	2014-10-14	2021-12-31	德克萨斯科技大学系统	Multiple shRNAs and application thereof

WO2016069716A1	2014-10-30	2016-05-06	The Scripps Research Institute	Compositions and methods comprising tyrosyl-trna synthetases and resveratrol compounds
GB201509202D0	2015-05-28	2015-07-15	Ge Healthcare Bio Sciences Ab	Semi-static cell culture
JP6924487B2	2015-06-10	2021-08-25	アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド	Non-embedded virus delivery system and how to use it
WO2017007994A1	2015-07-08	2017-01-12	American Gene Technologies International Inc.	Hiv pre-immunization and immunotherapy
JP6780870B2	2015-08-13	2020-11-04	北奥干細胞与再生医学研究院有限公司 B e i h a o S t e m C e l l A n d R e g e n e r a t i v e M e d i c i n e R e s e a r c h I n s t i t u t e C o . , L t d .	Induced expanded pluripotent stem cells, how to make and use
CN105112370B *	2015-08-25	2019-02-05	杭州优善生物科技有限公司	A kind of method and its application of stimulated in vitro peripheral blood gamma delta T cells high efficiently multiplying
JP7059179B2	2015-10-20	2022-04-25	アンスティチュ ナショナル ドウ ラ サンテ エ ドウ ラ シェル シュ メディカル	Methods and products for genetic engineering
US11389546B2	2015-12-09	2022-07-19	Modernatx, Inc.	Heterologous UTR sequences for enhanced mRNA expression
US10137144B2	2016-01-15	2018-11-27	American Gene Technologies International Inc.	Methods and compositions for the activation of gamma-delta T-cells
EP4310500A3	2016-01-15	2024-04-03	American Gene Technologies International Inc.	Methods and compositons for the activation of gamma-delta t-cells
EP3413926A4	2016-02-08	2019-10-09	American Gene Technologies International, Inc.	Hiv vaccination and immunotherapy
WO2017156311A2	2016-03-09	2017-09-14	American Gene Technologies International Inc.	Combination vectors and methods for treating cancer
BR112018069090A2	2016-03-23	2019-01-29	Univ New York State Res Found	cancer treatment based on distribution of oligos through communicating junctions from human mesenchymal stem cells (hmsc)
WO2017173453A1	2016-04-01	2017-10-05	The Brigham And Women's Hospital, Inc.	Stimuli-responsive nanoparticles for biomedical applications
JP7173548B2	2016-06-08	2022-11-16	アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド	Non-Integrating Viral Delivery Systems and Related Methods
AU2017292582C1	2016-07-08	2021-11-11	American Gene Technologies International Inc.	HIV pre-immunization and immunotherapy
EP3487507A4	2016-07-21	2020-04-08	American Gene Technologies International, Inc.	Viral vectors for treating parkinson's disease
KR20190100318A	2016-12-30	2019-08-28	더 트러스티스 오브 더 유니버시티 오브 펜실바니아	Gene therapy to treat phenylketonuria

EP3565564A4	2017-01-09	2020-09-23	American Gene Technologies International Inc.	Hiv immunotherapy with no pre-immunization step
CN110621322A	2017-02-08	2019-12-27	达纳-法伯癌症研究所有限公司	Modulatable endogenous protein degradation with heterobifunctional compounds
BR112019017839A2 *	2017-02-28	2020-04-14	Univ Pennsylvania	clade f vector of adeno-associated virus (aav) and its use
US11820999B2	2017-04-03	2023-11-21	American Gene Technologies International Inc.	Compositions and methods for treating phenylketonuria
US20200181645A1	2017-06-16	2020-06-11	American Gene Technologies International Inc.	Methods and compositions for the activation of tumor cytotoxicity via human gamma-delta t-cells
CN111433368A	2017-10-02	2020-07-17	美国基因技术国际有限公司	Vector with promoter and enhancer combination for treating phenylketonuria
DE112019000348B4	2018-01-05	2021-10-28	Nantbio, Inc.	REPROGRAMMED T-CELLS SIMILAR NK-CELLS
WO2020011247A1	2018-07-13	2020-01-16	Nanjing Legend Biotech Co., Ltd.	Co-receptor systems for treating infectious diseases
US11352646B2	2018-11-05	2022-06-07	American Gene Technologies International Inc.	Vector system for expressing regulatory RNA
KR20220068954A	2019-05-31	2022-05-26	아메리칸 진 테크놀로지스 인터내셔널 인코포레이티드	Optimized phenylalanine hydroxylase expression
IL296096A	2020-03-03	2022-11-01	American Gene Tech Int Inc	On demand expression of exogenous factors in lymphocytes to treat hiv

* Cited by examiner, † Cited by third party

Cited By (14)

Publication number	Priority date	Publication date	Assignee	Title
Family To Family Citations				
WO2010045659A1	2008-10-17	2010-04-22	American Gene Technologies International Inc.	Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
US10137144B2	2016-01-15	2018-11-27	American Gene Technologies International Inc.	Methods and compositions for the activation of gamma-delta T-cells
EP4310500A3	2016-01-15	2024-04-03	American Gene Technologies International Inc.	Methods and compositions for the activation of gamma-delta t-cells
EP3413926A4	2016-02-08	2019-10-09	American Gene Technologies International, Inc.	Hiv vaccination and immunotherapy
WO2017156311A2	2016-03-09	2017-09-14	American Gene Technologies	Combination vectors and methods for treating cancer

Publication	Publication Date	Publication Date	Title	Title
AU2017292582C1	2016-07-08	2021-11-11	American Gene Technologies International Inc.	HIV pre-immunization and immunotherapy
EP3487507A4	2016-07-21	2020-04-08	American Gene Technologies International, Inc.	Viral vectors for treating parkinson's disease
US11820999B2	2017-04-03	2023-11-21	American Gene Technologies International Inc.	Compositions and methods for treating phenylketonuria
US20200181645A1 *	2017-06-16	2020-06-11	American Gene Technologies International Inc.	Methods and compositions for the activation of tumor cytotoxicity via human gamma-delta t-cells
KR20200051011A *	2017-09-08	2020-05-12	제너레이션 바이오 컴퍼니	Modified closed-terminated DNA (CEDNA)
US11352646B2	2018-11-05	2022-06-07	American Gene Technologies International Inc.	Vector system for expressing regulatory RNA
CN109363955B *	2018-11-14	2021-09-21	广州玮弘祺生物科技有限公司	Solid styling spray for hair and preparation method thereof
CN109456993A *	2018-11-28	2019-03-12	上海安民生物技术有限公司	The albumin expression vectors of the promoter containing CAG
WO2020237219A1 *	2019-05-23	2020-11-26	Rocket Pharmaceuticals, Ltd.	Gene therapy vectors for infantile malignant osteopetrosis

* Cited by examiner, † Cited by third party, ‡ Family to family citation

Similar Documents

Publication	Publication Date	Title
IL279520A	2021-01-31	Methods and compositions for the activation of gamma-delta t-cells
IL271025A	2020-01-30	Multibiotic agents and methods of using the same
HK1252615A1	2019-05-31	Il-8-binding antibodies and uses thereof
IL266738A	2019-07-31	Novel antibodies and uses thereof
HK1249911A1	2018-11-16	Anti-muc16 antibodies and uses thereof
SG10201912199XA	2020-02-27	Anti-tim-3 antibodies and use thereof
HK1250238A1	2018-12-07	Anti-angptl8 antibodies and uses thereof
GB201706579D0	2017-06-07	Systems and methods for phone-as-a-key range extension
PH12017500877B1	2017-11-06	ANTI-CD79b ANTIBODIES AND METHODS OF USE
IL276515A	2020-09-30	Pd-l1-specific antibodies and methods of using the same

IL262095A	2018-11-29	Anti-pacap antibodies and uses thereof
EP3541840C0	2023-12-27	Anti-hla-g antibodies and use thereof
ZA201901935B	2020-11-25	Anti-il-33 antibodies and uses thereof
TW201613963A	2016-04-16	Anti-JAGGED1 antibodies and methods of use
GB201503387D0	2015-04-15	Anti-carbapenem antibodies and uses thereof
IL266049A	2019-06-30	Anti-o1 antibodies and uses thereof
PL3296048T3	2021-01-25	Dust-reduced saw and method of using the same
IL266082A	2019-06-30	Anti-chikv antibodies and uses thereof
IL264417A	2019-02-28	Anti-o2 antibodies and uses thereof
IL270719A	2020-01-30	Biopharmaceutical compositions and related methods
PL3565374T3	2023-08-28	Region configuration methods and devices
SG10201605375YA	2017-04-27	Sample holder and sample holder set
GB2563869B	2023-05-17	Materials and methods
MX2016016233A	2017-03-31	Anti-lgr5 antibodies and uses thereof.
HK1254240A1	2019-07-12	Anti-hypusine antibodies and uses thereof

Priority And Related Applications

Applications Claiming Priority (2)

Application	Filing date	Title
US201662279474P	2016-01-15	
PCT/US2017/013399	2017-01-13	Methods and compositons for the activation of gamma-delta t-cells

Legal Events

Date	Code	Title	Description
2021-05-31	FF	Patent granted	

2021-05-31

KB

Patent renewed

Concepts ▲

machine-extracted

[Download](#) Filter table ▼

Name	Image	Sections	Count	Query match
■ activation		title	1	0.000
■ gamma-delta t lymphocyte		title	1	0.000

[Show all concepts from the description section](#)

Data provided by IFI CLAIMS Patent Services

[About](#)

[Send Feedback](#)

[Public Datasets](#)

[Terms](#)

[Privacy Policy](#)

[Help](#)